|Articles|June 21, 2013

TransCelerate's Risk Based Monitoring Goes on Tour

Next week at DIA, two of TransCelerate?s Risk Based Monitoring workstream members will take their newly released methodology to the people.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Why Regulator-Sponsor Alignment Is Critical to Modernizing Trial Execution

ByRob DiCicco,Andy Studna, Senior Editor

July 6th 2026

When clinical trials are designed around the "ideal" engaged patient, the populations who need new treatments most are often the ones quietly screened out before the study even begins. Credit: Stock.Adobe.com/KHAN VECTOR CO.

Operational Pragmatism in ePRO-heavy trials

ByRakshinda Mujeeb, PharmD, CRCP, ACRP-CP

July 6th 2026

How Selective Safety Data Collection Could Make Pragmatic Trials Scalable

ByRob DiCicco

July 2nd 2026

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

ByAndy Studna, Senior Editor

July 2nd 2026

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

ByElizabeth Walsh, PMP, ACRP-CP

July 1st 2026

TransCelerate's Risk Based Monitoring Goes on Tour

Related Content

Why Regulator-Sponsor Alignment Is Critical to Modernizing Trial Execution

Operational Pragmatism in ePRO-heavy trials

How Selective Safety Data Collection Could Make Pragmatic Trials Scalable

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial

Trending on Applied Clinical Trials Online

ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation

Operational Pragmatism in ePRO-heavy trials

How Selective Safety Data Collection Could Make Pragmatic Trials Scalable

Why Regulator-Sponsor Alignment Is Critical to Modernizing Trial Execution